A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma-Reference-Cited by-同舟云学术

A multicenter phase II trial of single-agent cetuximab in advanced esophageal and gastric adenocarcinoma

Published:2011-06 Issue:6 Volume:22 Page:1367-1373
ISSN:0923-7534
Container-title:Annals of Oncology
language:en
Short-container-title:Annals of Oncology

Author:

Chan J.A.,Blaszkowsky L.S.,Enzinger P.C.,Ryan D.P.,Abrams T.A.,Zhu A.X.,Temel J.S.,Schrag D.,Bhargava P.,Meyerhardt J.A.,Wolpin B.M.,Fidias P.,Zheng H.,Florio S.,Regan E.,Fuchs C.S.

Publisher

Elsevier BV

Subject

Oncology,Hematology

Link

http://academic.oup.com/annonc/article-pdf/22/6/1367/579486/mdq604.pdf

Reference35 articles.

1. Patterns of cancer incidence, mortality, and prevalence across five continents: defining priorities to reduce cancer disparities in different geographic regions of the world;Kamangar;J Clin Oncol,2006

2. Rising incidence of adenocarcinoma of the esophagus and gastric cardia;Blot;JAMA,1991

3. Adenocarcinomas of the distal oesophagus and gastric cardia are one clinical entity. Rotterdam Oesophageal Tumour Study Group;Wijnhoven;Br J Surg,1999

4. Capecitabine and oxaliplatin for advanced esophagogastric cancer;Cunningham;N Engl J Med,2008

5. Randomized trial comparing epirubicin, cisplatin, and fluorouracil versus fluorouracil, doxorubicin, and methotrexate in advanced esophagogastric cancer;Webb;J Clin Oncol,1997

Cited by 98 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Drug Delivery Opportunities in Esophageal Cancer: Current Treatments and Future Prospects;Molecular Pharmaceutics;2024-06-18

2. DR30318, a novel tri-specific T cell engager for Claudin 18.2 positive cancers immunotherapy;Cancer Immunology, Immunotherapy;2024-03-30

3. Radiotherapy plus cetuximab or cisplatin in head and neck squamous cell carcinoma: an updated systematic review and meta-analysis of randomized controlled trials;European Archives of Oto-Rhino-Laryngology;2022-08-20

4. Toward Targeted Therapies in Oesophageal Cancers: An Overview;Cancers;2022-03-16

5. Safety and efficacy of anti-EGFR monoclonal antibody (SCT200) as second-line therapy in advanced esophageal squamous cell carcinoma;Cancer Biology & Medicine;2022-01-12